Trombophilic screening for nonarteritic anterior ischemic optic neuropathy

被引:28
作者
Nagy, V
Steiber, Z
Takacs, L
Vereb, G
Berta, A
Bereczky, Z
Pfliegler, G
机构
[1] Univ Debrecen, Dept Ophthalmol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary
[2] Univ Debrecen, Dept Biophys & Cell Biol, Med & Hlth Sci Ctr, Debrecen, Hungary
[3] Univ Debrecen, Div Rare Dis, Med & Hlth Sci Ctr, Debrecen, Hungary
[4] Univ Debrecen, Clin Res Ctr, Med & Hlth Sci Ctr, Debrecen, Hungary
关键词
NAION; anterior ischemic optic neuropathy; risk factors; thrombophilia;
D O I
10.1007/s00417-005-1154-5
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Nonarteritic anterior ischemic optic neuropathy (NAION) is an ischemic infarction of the optic nerve head, frequently leading to sudden, mostly irreversible loss of vision. In this study blood thrombophilic factors, as well as cardiovascular risk factors were investigated for their relevance to this pathology. Trombophilic risk factors so far not evaluated were included in the study. Patients and methods: 37 NAION patients (4 with sequential second eye involvement) and 81 matched control subjects were examined. From blood, protein C, protein S, antithrombin, von Willebrand antigen levels (vWFAg), and factor V (Leiden) mutation, factor VIIIC level, plasminogen activity, lipoprotein (a) and fibrinogen levels, and presence of anticardiolipin antibodies were investigated. Possibly relevant pathologies [e.g. diabetes mellitus (DM), hypertension, and ischemic heart disease] were also registered. Results: Elevated Lp(a) and vWFAg levels, DM, F V (Leiden), hypercholesterolemia, and hyperfibinogenemia proved to be significant risk factors associated with NAION. Forward stepwise logistic regression analysis revealed that high Lp(a), DM, and FV (Leiden) were the main predictive components, with odds ratios 16.88 (p=0.012), 5.78 (p=0.022) and 4.44 (p=0.033), respectively. Conclusions: Based on our results it appears that thrombophilia is likely to contribute to the development of NAION besides vascular damage due to the presence of cardiovascular risk factors. Further data are needed, however, to justify the suggested use of secondary prophylaxis using anticoagulant/antiplatelet therapy.
引用
收藏
页码:3 / 8
页数:6
相关论文
共 33 条
  • [1] Anterior ischaemic optic neuropathy associated with central retinal vein occlusion
    Abu El-Asrar, AM
    Al Rashaed, SA
    Gader, AGMA
    [J]. EYE, 2000, 14 (4) : 560 - 562
  • [2] COAGULATION ABNORMALITIES IN ISCHEMIC OPTIC NEUROPATHY
    ACHESON, JF
    SANDERS, MD
    [J]. EYE, 1994, 8 : 89 - 92
  • [3] APARICIO S, 1996, BIOCHEM J, V15, P467
  • [4] Aspirin therapy in nonarteritic anterior ischemic optic neuropathy
    Beck, RW
    Hayreh, SS
    Podhajsky, PA
    Tan, ES
    Moke, PS
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 123 (02) : 212 - 217
  • [5] BECK RW, 1987, OPHTHALMOLOGY, V94, P1503
  • [6] BERI M, 1987, OPHTHALMOLOGY, V94, P1020
  • [7] MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C
    BERTINA, RM
    KOELEMAN, BPC
    KOSTER, T
    ROSENDAAL, FR
    DIRVEN, RJ
    DERONDE, H
    VANDERVELDEN, PA
    REITSMA, PH
    [J]. NATURE, 1994, 369 (6475) : 64 - 67
  • [8] CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
  • [9] Recurrent optic nerve head infarctions associated with combined factor V Leiden- and factor II:G20210A-mutation
    Cursiefen, C
    Schönherr, U
    Schwender, S
    Grossmann, R
    [J]. ACTA OPHTHALMOLOGICA SCANDINAVICA, 1999, 77 (06): : 625 - 627
  • [10] Activated protein C resistance and thrombosis:: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation
    Dahlbäck, B
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (03) : 273 - 289